PENG Block Optimization: Volume and Dexamethasone Effects
Key facts
- Who runs it
- Poznan University of Medical Sciences
- Where
- Poland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 120 people enrolled
- Started
- 25 Jun 2025
- Ended
- 20 Feb 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ropivacaine 0.2% Injectable Solution
- Dexamethasone 4mg
- Record updated
- 16 March 2026
Who can take part
- Age
- 60 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Adults aged ≥18 years scheduled for primary unilateral total hip arthroplasty (THA)
- American Society of Anesthesiologists (ASA) physical status I-III
- Ability to provide written informed consent
- Spinal anesthesia planned as the primary anesthetic technique
- Body mass index (BMI) between 18 and 35 kg/m²
- Fluent in the local language and able to understand the NRS pain scoring system
Who cannot take part
- Chronic opioid use (daily use >30 mg oral morphine equivalents for >1 month prior to surgery)
- Previous surgery or implantation on the ipsilateral hip
- Known allergy or hypersensitivity to ropivacaine, dexamethasone, or other amide local anesthetics
- History of coagulopathy, current anticoagulant therapy not eligible for regional anesthesia
- Uncontrolled diabetes mellitus (HbA1c > 9%) or active systemic infection
- Pre-existing neurological deficits or neuropathies affecting lower limb motor or sensory function
- Pregnancy or breastfeeding
- Inability to cooperate with postoperative assessments or participate in follow-up
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized controlled trial investigates the impact of local anesthetic volume and perineural dexamethasone on the analgesic and anti-inflammatory effectiveness of the pericapsular nerve group (PENG) block in patients undergoing total hip arthroplasty (THA). Patients were randomized to receive one of four PENG block variants differing in ropivacaine volume (10 mL or 20 mL of 0.2%) and the addition of 4 mg of perineural dexamethasone. The study evaluates postoperative pain, opioid requirements, systemic inflammatory markers, and quadriceps motor preservation.
The 4 groups in the trial
- PENG 20 mLExisting treatment, for comparison
Ultrasound-guided PENG block - 20ml 0,2% ropivacaine
Treatment: Ropivacaine 0.2% Injectable Solution
- PENG 20 mL + DEXExisting treatment, for comparison
Ultrasound-guided PENG block - 20ml 0,2% ropivacaine + 4mg Dexamethasone
Treatment: Ropivacaine 0.2% Injectable Solution and Dexamethasone 4mg
- PENG 10 mLExisting treatment, for comparison
Ultrasound-guided PENG block - 10ml 0,2% ropivacaine
Treatment: Ropivacaine 0.2% Injectable Solution
- PENG 10 mL + DEXExisting treatment, for comparison
Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone
Treatment: Dexamethasone 4mg and Ropivacaine 0.2% Injectable Solution
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optimizing PENG Block in Hip Arthroplasty: Influence of Ropivacaine Volume and Dexamethasone on Analgesic Efficacy
- Record updated
- 16 March 2026